Skip to main content
. 2025 Feb 16;15(2):e70189. doi: 10.1002/ctm2.70189

FIGURE 3.

FIGURE 3

Functional relevance of the 5hmC‐based predict marker for in colorectal cancer. (A) Venn diagram indicating overlap and specificity of increase or decrease in PC patients and MLM patients from 5hmC‐Seal. (B) Boxplots of PDE4D 5hmC FPKM (Fragments per kilobase of gene per million mapped reads) in PC, SLM and MLM groups. Welch t‐test was used. (C) Boxplots of PDE4D 5hmC FPKM (Fragments per kilobase of gene per million mapped reads) in gDNA of tissue samples. Welch t‐test was used. (D) Quantitative comparison of PDE4D 5hmC levels in PN and PT. The two dots connected are samples from the same patient. (E) Quantitative comparison of PDE4D 5hmC levels in MPN and MPT. (F) Correlation plots of the source of cfDNA with the source of tissue gDNA in PDE4D. (G) The overall survival time (OS, months) and event free survival (EFS, months) of patients with different 5hmC level of PDE4D in 133 portal vein blood samples. (H) Immunohistochemical detection of PDE4D expression in normal tissue, colorectal tumour tissue (primary), colorectal tumour tissue (metastases) and liver tumour tissue (n = 15). Scale bar, 100 mm. (I) ROC curve of the classification model of liver metastases with 5hmC level and protein expression level of PDE4D. *p < .05; **p < .01; ***p < .001. CTT: colorectal tumour tissue, LTT: liver tumour tissue.